Mime-Version: |
1.0 |
Content-Type: |
text/plain; charset="UTF-8" |
Date: |
Thu, 18 Jan 2018 19:55:48 -0500 |
Reply-To: |
|
Subject: |
|
Content-Transfer-Encoding: |
quoted-printable |
Message-ID: |
|
Sender: |
|
From: |
|
Parts/Attachments: |
|
|
> The antibiotics that are being regulated are ones that are medically important to humans. Reading that list, you do not find Fumagilin [sic].
! It is a very important human drug, it's just not being classified as an antibiotic !
> Enterocytozoon bieneusi microsporidiosis is an emerging disease in immunocompromised patients. We report 2 cases of this disease in allogeneic hematopoietic stem cell transplant patients successfully treated with fumagillin.
> Enterocytozoon bieneusi, the most common cause of microsporidiosis in humans (1), causes chronic diarrhea and severe wasting syndrome in immunocompromised patients (2). In 2002, oral fumagillin was established as an effective treatment for E. bieneusi microsporidiosis in HIV-infected and solid organ transplant (SOT) patients (3). In contrast to previous treatments that did not result in parasitologic clearance or clinical remission, fumagillin showed a cure rate of 100%, even for severely immunocompromised patients.
> In conclusion, fumagillin was highly efficient in curing E. bieneusi microsporidiosis in 2 allogeneic HSCT recipients. Thrombocytopenia occurred but without major adverse events. Modifications to immunosuppression could be avoided when E. bieneusi is rapidly identified and fumagillin therapy is started promptly.
Enterocytozoon bieneusi Microsporidiosis in Stem Cell Transplant Recipients Treated with Fumagillin
Emerg Infect Dis. 2017 Jun; 23(6): 1039–1041.
***********************************************
The BEE-L mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|